Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Receivables (2023 - 2025)

Telix Pharmaceuticals has reported Receivables over the past 3 years, most recently at $1.3 million for Q4 2025.

  • Quarterly Receivables fell 98.62% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, down 98.62% year-over-year, with the annual reading at $1.3 million for FY2025, 98.62% down from the prior year.
  • Receivables was $1.3 million for Q4 2025 at Telix Pharmaceuticals, down from $93.0 million in the prior quarter.
  • Over five years, Receivables peaked at $93.0 million in Q4 2024 and troughed at $1.3 million in Q4 2025.
  • The 3-year median for Receivables is $43.7 million (2023), against an average of $46.0 million.
  • Year-over-year, Receivables surged 112.85% in 2024 and then plummeted 98.62% in 2025.
  • A 3-year view of Receivables shows it stood at $43.7 million in 2023, then surged by 112.85% to $93.0 million in 2024, then plummeted by 98.62% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for TLX's Receivables are $1.3 million (Q4 2025), $93.0 million (Q4 2024), and $43.7 million (Q4 2023).